- Home
- EHI vs BDTX Comparison
EHI vs BDTX Comparison
Compare EHI & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHI
- BDTX
- Stock Information
- Founded
- EHI 2003
- BDTX 2014
- Country
- EHI United States
- BDTX United States
- Employees
- EHI N/A
- BDTX N/A
- Industry
- EHI Investment Managers
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EHI Finance
- BDTX Health Care
- Exchange
- EHI Nasdaq
- BDTX Nasdaq
- Market Cap
- EHI 194.8M
- BDTX 181.4M
- IPO Year
- EHI N/A
- BDTX 2020
- Fundamental
- Price
- EHI $6.40
- BDTX $3.78
- Analyst Decision
- EHI
- BDTX Strong Buy
- Analyst Count
- EHI 0
- BDTX 5
- Target Price
- EHI N/A
- BDTX $10.40
- AVG Volume (30 Days)
- EHI 44.5K
- BDTX 1.0M
- Earning Date
- EHI 01-01-0001
- BDTX 11-05-2025
- Dividend Yield
- EHI 11.54%
- BDTX N/A
- EPS Growth
- EHI N/A
- BDTX N/A
- EPS
- EHI N/A
- BDTX 0.25
- Revenue
- EHI N/A
- BDTX $70,000,000.00
- Revenue This Year
- EHI N/A
- BDTX N/A
- Revenue Next Year
- EHI N/A
- BDTX N/A
- P/E Ratio
- EHI N/A
- BDTX $15.92
- Revenue Growth
- EHI N/A
- BDTX N/A
- 52 Week Low
- EHI $6.00
- BDTX $1.20
- 52 Week High
- EHI $7.75
- BDTX $4.45
- Technical
- Relative Strength Index (RSI)
- EHI 34.86
- BDTX 51.12
- Support Level
- EHI $6.35
- BDTX $3.88
- Resistance Level
- EHI $6.42
- BDTX $4.45
- Average True Range (ATR)
- EHI 0.06
- BDTX 0.28
- MACD
- EHI -0.01
- BDTX -0.04
- Stochastic Oscillator
- EHI 17.76
- BDTX 13.46
About EHI Western Asset Global High Income Fund Inc
Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income and total return by investing in a world-wide portfolio of securities. The fund invests in various sectors such as Consumer Discretionary, Energy, Healthcare, Industrials, materials, and others.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.